{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T15:33:30Z","timestamp":1781796810790,"version":"3.54.5"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T00:00:00Z","timestamp":1560124800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T00:00:00Z","timestamp":1560124800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA189163"],"award-info":[{"award-number":["CA189163"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA29605"],"award-info":[{"award-number":["CA29605"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1245\/s10434-019-07487-5","type":"journal-article","created":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T18:10:49Z","timestamp":1560190249000},"page":"4610-4618","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Impact of Effective Systemic Therapy on Metastasectomy in Stage IV Melanoma: A Matched-Pair Analysis"],"prefix":"10.1245","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1555-819X","authenticated-orcid":false,"given":"Daniel W.","family":"Nelson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevan D.","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda N.","family":"Graff-Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Dehal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey","family":"Stern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton J.","family":"Bilchik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark B.","family":"Faries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,10]]},"reference":[{"issue":"16","key":"7487_CR1","doi-asserted-by":"publisher","first-page":"3622","DOI":"10.1200\/JCO.2001.19.16.3622","volume":"19","author":"CM Balch","year":"2001","unstructured":"Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19(16):3622\u201334.","journal-title":"J Clin Oncol."},{"issue":"9","key":"7487_CR2","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1001\/archsurg.1996.01430210073013","volume":"131","author":"DW Ollila","year":"1996","unstructured":"Ollila DW, Essner R, Wanek LA, Morton DL. Surgical resection for melanoma metastatic to the gastrointestinal tract. Arch Surg. 1996;131(9):975\u201380.","journal-title":"Arch Surg."},{"issue":"9","key":"7487_CR3","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1001\/archsurg.139.9.961","volume":"139","author":"R Essner","year":"2004","unstructured":"Essner R, Lee JH, Wanek LA, Itakura H, Morton DL. Contemporary surgical treatment of advanced-stage melanoma. Arch Surg. 2004;139(9):961\u20136 (discussion 966\u2013967)","journal-title":"Arch Surg."},{"issue":"20","key":"7487_CR4","doi-asserted-by":"publisher","first-page":"4740","DOI":"10.1002\/cncr.26111","volume":"117","author":"JA Sosman","year":"2011","unstructured":"Sosman JA, Moon J, Tuthill RJ, et al. A phase 2 trial of complete resection for stage IV melanoma: results of Southwest Oncology Group Clinical Trial S9430. Cancer. 2011;117(20):4740\u201360.","journal-title":"Cancer."},{"issue":"8","key":"7487_CR5","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1245\/s10434-012-2398-z","volume":"19","author":"JH Howard","year":"2012","unstructured":"Howard JH, Thompson JF, Mozzillo N, et al. Metastasectomy for distant metastatic melanoma: analysis of data from the first Multicenter Selective Lymphadenectomy Trial (MSLT-I). Ann Surg Oncol. 2012;19(8):2547\u201355.","journal-title":"Ann Surg Oncol."},{"issue":"1","key":"7487_CR6","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jamcollsurg.2014.04.008","volume":"219","author":"MB Faries","year":"2014","unstructured":"6. Faries MB, Leung A, Morton DL, et al. A 20-year experience of hepatic resection for melanoma: is there an expanding role? J Am Coll Surg. 2014;219(1):62\u20138.","journal-title":"J Am Coll Surg."},{"issue":"10","key":"7487_CR7","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1177\/000313481508101019","volume":"81","author":"DC Flaherty","year":"2015","unstructured":"Flaherty DC, Deutsch GB, Kirchoff DD, et al. Adrenalectomy for metastatic melanoma: current role in the age of nonsurgical treatments. Am Surg. 2015;81(10):1005\u20139.","journal-title":"Am Surg."},{"issue":"11","key":"7487_CR8","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1177\/000313481608201128","volume":"82","author":"S Prabhakaran","year":"2016","unstructured":"Prabhakaran S, Fulp WJ, Gonzalez RJ, et al. Resection of gastrointestinal metastases in stage IV melanoma: correlation with outcomes. Am Surg. 2016;82(11):1109\u201316.","journal-title":"Am Surg."},{"issue":"13","key":"7487_CR9","doi-asserted-by":"publisher","first-page":"3991","DOI":"10.1245\/s10434-017-6072-3","volume":"24","author":"MB Faries","year":"2017","unstructured":"9. Faries MB, Mozzillo N, Kashani-Sabet M, et al. Long-term survival after complete surgical resection and adjuvant immunotherapy for distant melanoma metastases. Ann Surg Oncol. 2017;24(13):3991\u20134000.","journal-title":"Ann Surg Oncol."},{"issue":"8","key":"7487_CR10","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711\u201323.","journal-title":"N Engl J Med."},{"issue":"26","key":"7487_CR11","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","volume":"364","author":"C Robert","year":"2011","unstructured":"Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517\u201326.","journal-title":"N Engl J Med."},{"issue":"26","key":"7487_CR12","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","volume":"364","author":"PB Chapman","year":"2011","unstructured":"Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507\u201316.","journal-title":"N Engl J Med."},{"issue":"26","key":"7487_CR13","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521\u201332.","journal-title":"N Engl J Med."},{"issue":"1","key":"7487_CR14","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"14. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23\u201334.","journal-title":"N Engl J Med."},{"issue":"1","key":"7487_CR15","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1056\/NEJMoa1412690","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372(1):30\u20139.","journal-title":"N Engl J Med."},{"issue":"4","key":"7487_CR16","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/(SICI)1096-9098(199812)69:4<206::AID-JSO3>3.0.CO;2-N","volume":"69","author":"DW Ollila","year":"1998","unstructured":"Ollila DW, Stern SL, Morton DL. Tumor doubling time: a selection factor for pulmonary resection of metastatic melanoma. J Surg Oncol. 1998;69(4):206\u201311.","journal-title":"J Surg Oncol."},{"issue":"9","key":"7487_CR17","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1002\/1097-0142(20001101)89:9<1983::AID-CNCR15>3.3.CO;2-J","volume":"89","author":"T Meyer","year":"2000","unstructured":"Meyer T, Merkel S, Goehl J, Hohenberger W. Surgical therapy for distant metastases of malignant melanoma. Cancer. 2000;89(9):1983-1991.","journal-title":"Cancer."},{"issue":"8","key":"7487_CR18","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.ctrv.2007.06.004","volume":"33","author":"P Lui","year":"2007","unstructured":"Lui P, Cashin R, Machado M, Hemels M, Corey-Lisle PK, Einarson TR. Treatments for metastatic melanoma: synthesis of evidence from randomized trials. Cancer Treat Rev. 2007;33(8):665\u201380.","journal-title":"Cancer Treat Rev."},{"issue":"12","key":"7487_CR19","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1016\/S1470-2045(16)30578-2","volume":"17","author":"GV Long","year":"2016","unstructured":"Long GV, Grob JJ, Nathan P, et al. Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. Lancet Oncol. 2016;17(12):1743\u201354.","journal-title":"Lancet Oncol."},{"issue":"19","key":"7487_CR20","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","volume":"377","author":"J Weber","year":"2017","unstructured":"Weber J, Mandala M, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377(19):1824\u201335.","journal-title":"N Engl J Med."},{"issue":"7","key":"7487_CR21","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1200\/JCO.2017.74.1025","volume":"36","author":"GV Long","year":"2018","unstructured":"Long GV, Eroglu Z, Infante J, et al. Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma who received dabrafenib combined with trametinib. J Clin Oncol. 2018;36(7):667\u201373.","journal-title":"J Clin Oncol."},{"issue":"9","key":"7487_CR22","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1038\/bjc.2017.70","volume":"116","author":"A Nosrati","year":"2017","unstructured":"Nosrati A, Tsai KK, Goldinger SM, et al. Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy. Br J Cancer. 2017;116(9):1141\u20137.","journal-title":"Br J Cancer."},{"issue":"7652","key":"7487_CR23","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/nature22079","volume":"545","author":"AC Huang","year":"2017","unstructured":"Huang AC, Postow MA, Orlowski RJ, et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature. 2017;545(7652):60\u20135.","journal-title":"Nature."},{"issue":"19","key":"7487_CR24","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","volume":"377","author":"GV Long","year":"2017","unstructured":"Long GV, Hauschild A, Santinami M, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med. 2017;377(19):1813\u201323.","journal-title":"N Engl J Med."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-019-07487-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-019-07487-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-019-07487-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T03:52:38Z","timestamp":1608263558000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-019-07487-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,10]]},"references-count":24,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["7487"],"URL":"https:\/\/doi.org\/10.1245\/s10434-019-07487-5","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,10]]},"assertion":[{"value":"23 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The results and opinions expressed in this article are those of the authors and do not reflect the opinions or official policy of the United States Army or the Department of Defense. The content of this report is solely the responsibility of the authors and does not necessarily represent the official view of the National Cancer Institute or the National Institutes of Health.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}